演題抄録

ポスター

開催概要
開催回
第56回・2018年・横浜
 

高齢もしくは脆弱な進行再発大腸癌症例に対するCapecitabine+Bevacizumab療法

演題番号 : P19-2

[筆頭演者]
演者)玉川 浩司:1 
[共同演者]
文元 雄一:1、谷口 英治:1、新田 佳苗:1、松浦 雄祐:1、中場 寛行:1、土屋 裕貴:2、倉橋 基尚:2

1:大手前病院・外科、2:大手前病院・薬剤部

 


Combination therapy with fluorouracil and anti-vascular endothelial growth factor (a-VEGF) is one of the recommended options for elderly and or frail patients with metastatic colorectal cancer. We explored the efficacy and safety of capecitabine plus bevacizumab therapy for those patients in our institution.

Between 2013 and 2017, elderly (80 years old or elder) or frail patients with metastatic colorectal carcinoma treated with capecitabine plus bevacizumab therapy as the first line therapy were eligible for this analysis. Histopathological characteristics and efficacy together with safety of the therapy was examined by medical records retrospectively.

Nine patients were included in this analysis. Those patients included 5 elderly and 4 frail cases, whose median age was 80 year old. Seven of the 9 patients showed mutant RAS status, though 1 patient was not examined. Median duration of the treatment was 8 months. The initial capecitabine dose was 2000mg/m2 in 2, 1500mg/m2 in 7. Five of the 9 patients underwent dose reduction in capecitabine during the following treatment. The optimal response included partial response (PR) in 1, stable disease (SD) in 6, and progression disease (PD) in 2 patients. The reason of treatment discontinuation was PD in all cases. Six of the 9 cases continued the treatment even after the judgement as PD.

Capecitabine plus bevacizumab therapy should be one of the options for elderly or frail patients with metastatic colorectal cancer, although most of the response might be SD. Dose arrangement of capecitabine would be considered in those population.

キーワード

臓器別:大腸・小腸

手法別:化学療法

前へ戻る